The rhd gene is a fundamental component of the Rhesus (Rh) blood group system, encoding the RhD antigen that defines an individual’s Rh status as positive or negative. This protein is a transmembrane polypeptide that functions as an ammonia channel and plays a critical role in the structural integrity of the red blood cell membrane. The presence or absence of the RhD antigen on the surface of erythrocytes is the most significant immunogenic factor in blood transfusion medicine and a primary concern in obstetrics, particularly regarding hemolytic disease of the fetus and newborn (HDFN).
Molecular Biology and Genetics
Located on the short arm of chromosome 1 at position 34.1 (1p34.1), the RHD gene is highly homologous to the adjacent RHCE gene. This genetic proximity facilitates frequent recombination events, leading to the existence of hybrid genes and variations in gene copy number. The RhD protein is a glycosylated polypeptide consisting of 417 amino acids, and its expression is regulated by multiple transcription factors. Polymorphisms within the RHD gene, including single nucleotide polymorphisms and partial deletions, are the direct cause of RhD-negative phenotypes, which vary significantly in frequency across different ethnic populations.
Clinical Significance in Transfusion Medicine
In transfusion medicine, the Rhd gene status is paramount for ensuring compatibility between donors and recipients. Individuals who are RhD-negative (lacking the antigen) can produce anti-D antibodies upon exposure to RhD-positive red blood cells, typically during transfusion or pregnancy. These antibodies can cause severe hemolytic transfusion reactions, making it essential to screen for the RhD antigen and phenotype blood units accurately. For patients with rare Rh phenotypes, identifying the specific molecular basis of RhD expression is crucial for finding compatible blood supplies.
Antibody Formation and Sensitization
RhD-negative individuals do not possess the RhD antigen, which their immune system recognizes as foreign. Exposure to RhD-positive blood, through transfusion or fetomaternal hemorrhage, triggers an immune response that produces anti-D immunoglobulin G (IgG) antibodies. Once formed, these antibodies can cross the placenta in subsequent pregnancies, attacking the RhD-positive red blood cells of the fetus and leading to HDFN. This immune response is the primary reason for administering RhD immune globulin (RhIg) to Rh-negative mothers postpartum.
Obstetric Implications and HDFN
The rhd gene plays a vital role in maternal-fetal medicine, where Rh incompatibility poses a significant risk. If an RhD-negative mother carries an RhD-positive fetus, there is a potential for the mother’s immune system to become sensitized. This sensitization can result in the production of antibodies that cross the placenta and destroy fetal red blood cells, causing anemia, jaundice, hydrops fetalis, or even intrauterine death. Modern antenatal care includes screening for anti-D antibodies and prophylactic RhIg administration to prevent sensitization.
Prevention and Management Strategies
Standard practice involves testing the blood type and Rh status of all pregnant women early in gestation. If an Rh-negative mother is identified, she receives an injection of RhIg around the 28th week of pregnancy and again within 72 hours after delivery if the baby is Rh-positive. This prophylaxis works by binding to any fetal RhD-positive red blood cells that entered the maternal circulation, preventing her immune system from recognizing them and mounting a response. In cases where HDFN has already occurred, intrauterine blood transfusions or early delivery may be necessary.
Global Distribution and Population Genetics
The frequency of the RhD-negative phenotype varies dramatically worldwide, indicating a strong genetic and evolutionary influence. The trait is most common in individuals of European descent, with prevalence rates of 15-20% in Caucasian populations. In contrast, it is relatively rare in people of African and Asian ancestry, with frequencies dropping below 1% in some East Asian groups. This geographic distribution suggests that the RhD-negative trait may have conferred a selective advantage, possibly related to resistance to certain infectious diseases like toxoplasmosis.
